iTeos Therapeutics, Inc. (ITOS) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2025-08-29

iTeos Therapeutics, Inc. (ITOS) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every ITOS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About iTeos Therapeutics, Inc. (ITOS)

SEC CIK	0001808865

Recent ITOS Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-08-29	McGrath Yvonne	Chief Scientific Officer	J — Other acquisition / disposition	46.3K	—	—	SEC
2025-08-29	Detheux Michel	Chief Executive Officer	J — Other acquisition / disposition	153.9K	—	—	SEC
2025-08-29	Detheux Michel	Chief Executive Officer	J — Other acquisition / disposition	94.0K	—	—	SEC
2025-08-29	Call Matthew	Chief Operating Officer	J — Other acquisition / disposition	161.9K	—	—	SEC
2025-08-29	Feltquate David	Chief Medical Officer	J — Other acquisition / disposition	47.0K	—	—	SEC
2025-08-29	Gall Matthew	Chief Financial Officer	J — Other acquisition / disposition	89.4K	—	—	SEC
2025-05-13	GADICKE ANSBERT	Insider	S — Open-market sale	1.03M	$8.06	$8.32M	SEC
2025-05-13	MPM BioVentures 2014, L.P.	Insider	S — Open-market sale	630.2K	$8.06	$5.08M	SEC
2024-12-06	Feltquate David	Chief Medical Officer	A — Grant or award	47.0K	$0.00	—	SEC
2024-11-19	Gall Matthew	Chief Financial Officer	P — Open-market purchase	5.0K	$7.73	$39K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for iTeos Therapeutics, Inc. (ITOS). Updated in real time as new filings are submitted to the SEC.

Recent Insider Filings

2025-08-29 — Hallal David (Insider)
2025-08-29 — McGrath Yvonne (Chief Scientific Officer)
2025-08-29 — Detheux Michel (Chief Executive Officer)
2025-08-29 — Call Matthew (Chief Operating Officer)
2025-08-29 — RHOADS ANN D (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ITOS insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

ITOS Insider Trading — FAQ

What is the latest insider trade for ITOS?: iTeos Therapeutics, Inc. (ITOS) had 0 insider filings in the last 90 days, with the most recent on 2025-08-29. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ITOS stock?: 0 insider purchases of ITOS were filed in the last 90 days.
How many insiders are selling ITOS stock?: 0 insider sales of ITOS were filed in the last 90 days.
Where can I see ITOS SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every ITOS SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live ITOS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.